Labcorp (LH) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 27, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Amy B. Summy, Evp, Chief Marketing Officer sold 365 shares at $372.58 ($136K).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All LH insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
LH insider transactions (Form 4)
Open-market purchases and sales. 133 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Amy B. SummyEvp, Chief Marketing Officer | Sell | 3656,590 held (−5%) | $372.58 | $136K | -1.0% | — |
| Nov 12SEC | Brian J. CaveneyEvp, Pres Of Bls, Cmo & Cso | Sell | 2,00034,562 held (−5%) | $372.04 | $744K | -0.8% | — |
| Nov 5SEC | Bryan T. VaughnPresident | Sell Plan | 3066,845 held (−4%) | $353.70 | $108K | +4.3% | — |
| Nov 3SEC | Richelle P. ParhamDirector | Sell | 1,0782,288 held (−32%) | $361.22 | $389K | +2.2% | — |
| Aug 18SEC | Kerrii B. AndersonDirector | Sell Plan | 3,0006,563 held (−31%) | $318.02 | $954K | +16.0% | — |
| Aug 12SEC | Adam H. SchechterCEO, President | Sell Plan | 4,669102,565 held (−4%) | $320.37 | $1.5M | +15.2% | — |
| Aug 6SEC | Amy B. SummyEvp, Chief Marketing Officer | Sell | 9246,956 held (−12%) | $306.74 | $283K | +20.3% | — |
| Aug 5SEC | Peter J. WilkinsonSvp, Chief Accounting Officer | Sell | 1,3381,770 held (−43%) | $309.23 | $414K | +19.3% | — |
| Aug 5SEC | Peter J. WilkinsonSvp, Chief Accounting Officer | Sell | 821,770 held (−4%) | $309.22 | $25K | +19.3% | — |
| Jul 6SEC | Bryan T. VaughnPresident | Sell Plan | 2346,746 held (−3%) | $286.19 | $67K | +28.9% | — |
| Jul 6SEC | Kathryn W. KyleGeneral Counsel | Sell Plan | 923,904 held (−2%) | $286.19 | $26K | +28.9% | — |
| Jun 10SEC | Kathryn W. KyleGeneral Counsel | Sell Plan | 7623,813 held (−17%) | $263.89 | $201K | +39.8% | — |
| May 13SEC | Adam H. SchechterCEO, President | Sell Plan | 5,903107,234 held (−5%) | $254.50 | $1.5M | +45.0% | — |
| Mar 30SEC | Peter J. WilkinsonSvp, Chief Accounting Officer | Sell Plan | 1,6331,852 held (−47%) | $267.05 | $436K | +38.2% | — |
| Mar 30SEC | Jonathan C. MeltzerEvp, Operations | Sell Plan | 8393,620 held (−19%) | $267.05 | $224K | +38.2% | — |
| Mar 5SEC | Adam H. SchechterCEO, President | Sell | 8,70580,773 held (−10%) | $279.96 | $2.4M | +31.8% | — |
| Mar 3SEC | Der Vaart Sandra D. VanEvp, Corporate Affairs | Sell | 5482,579 held (−18%) | $284.91 | $156K | +29.5% | — |
| Feb 26SEC | Brian J. CaveneyEvp, Pres Of Ed, Cmo & Cso | Sell | 1,50030,107 held (−5%) | $286.31 | $429K | +28.9% | — |
| Feb 23SEC | Peter J. WilkinsonSvp, Chief Accounting Officer | Sell Plan | 6661,852 held (−26%) | $277.94 | $185K | +32.8% | — |
| Feb 13SEC | Adam H. SchechterCEO, President | Sell Plan | 5,27387,343 held (−6%) | $284.38 | $1.5M | +29.8% | — |
| Feb 13SEC | Jonathan C. MeltzerEvp, Operations | Sell Plan | 872,782 held (−3%) | $290.42 | $25K | +27.1% | — |
| Feb 12SEC | Jonathan C. MeltzerEvp, Operations | Sell Plan | 912,696 held (−3%) | $276.79 | $25K | +33.3% | — |
| Feb 10SEC | Jonathan C. MeltzerEvp, Operations | Sell Plan | 882,869 held (−3%) | $275.53 | $24K | +33.9% | — |
| Nov 13SEC | Adam H. SchechterCEO, President | Sell Plan | 5,74587,574 held (−6%) | $262.75 | $1.5M | +40.4% | — |
| Nov 4SEC | Richelle P. ParhamDirector | Sell | 7,0092,469 held (−74%) | $254.28 | $1.8M | +45.1% | — |
Similar past setups: not applicable. LH has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with LH in the Research Lab
LH has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Labcorp insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 10 sold $11.8M of LH stock on the open market; P/E 25.5 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
LH insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $1.4M | 4 |
| Q3 2026 | — | 0 | $3.3M | 7 |
| Q2 2026 | — | 0 | $1.7M | 2 |
| Q1 2026 | — | 0 | $5.4M | 10 |
| Q4 2025 | — | 0 | $3.3M | 2 |
Valuation, profit and volume
Source: Yahoo Finance, as of Oct 5, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Labcorp insiders reported open-market purchases totaling $0, while 10 insiders reported sales totaling $11.8M. 15 of 25 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
LH earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 28, 2026 | +5.0% | None | +11.2%S&P -0.0% | pending |
| Jul 30, 2026 | +11.4% | Sold $93K | +0.7%S&P +2.4% | +8.6% |
| Apr 30, 2026 | -4.4% | None | -0.5%S&P +1.3% | +1.9% |
| Feb 17, 2026 | +4.8% | Sold $1.6M | -1.4%S&P +0.7% | -5.4% |
| Oct 28, 2025 | -0.8% | None | -10.0%S&P +0.3% | +8.6% |
| Jul 24, 2025 | -2.7% | None | +5.8%S&P +0.5% | +5.0% |
| Apr 29, 2025 | +3.7% | None | +5.0%S&P +0.7% | +3.6% |
| Feb 6, 2025 | +2.5% | None | -1.5%S&P -0.6% | +3.0% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
LH short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Members of Congress who traded LH
From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.
| Member | Trade | Traded | Reported | Since trade |
|---|---|---|---|---|
| Alan ArmstrongSenate | Bought $1,001 - $15,000 | Mar 27, 2026 | Jul 21, 2026 | +40.4% |
Insiders at Labcorp
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Adam H. SchechterCEO, President | — | $8.4M | Aug 12, 2026 | — | — |
| Richelle P. ParhamDirector | — | $2.2M | Nov 3, 2026 | — | — |
| Brian J. CaveneyEvp, Pres Of Bls, Cmo & Cso | — | $1.2M | Nov 12, 2026 | — | — |
| Peter J. WilkinsonSvp, Chief Accounting Officer | — | $1.1M | Aug 5, 2026 | — | — |
| Kerrii B. AndersonDirector | — | $954K | Aug 18, 2026 | 0 of 2 | — |
| Amy B. SummyEvp, Chief Marketing Officer | — | $419K | Nov 18, 2026 | — | — |
| Jonathan C. MeltzerEvp, Operations | — | $299K | Mar 30, 2026 | — | — |
| Kathryn W. KyleGeneral Counsel | — | $227K | Jul 6, 2026 | — | — |
| Bryan T. VaughnPresident | — | $175K | Nov 5, 2026 | — | — |
| Der Vaart Sandra D. VanEvp, Corporate Affairs | — | $156K | Mar 30, 2026 | — | — |
| Akinbolade OyegunwaCTO | — | — | Nov 3, 2026 | — | — |
| Mark S. SchroederCOO | — | — | Mar 30, 2026 | — | — |
| Anita Z. GrahamEvp, Chro | — | — | Mar 30, 2026 | — | — |
| Megan D. BaileyEvp, Pres, Central Labs & Intl | — | — | Mar 30, 2026 | — | — |
| Julia Aijun WangCFO | — | — | Feb 13, 2026 | — | — |
| Jeffrey A. DavisDirector | — | — | Feb 13, 2026 | — | — |
| Kirsten Marie KliphouseDirector | — | — | Feb 13, 2026 | — | — |
| Garheng KongDirector | — | — | Feb 13, 2026 | — | — |
| Peter M. NeupertDirector | — | — | Feb 13, 2026 | — | — |
| Kathryn E. WengelDirector | — | — | Feb 13, 2026 | — | — |
| Paul RothmanDirector | — | — | Feb 13, 2026 | — | — |
Board links: companies that share insiders with LH
Directors and executives who filed Form 4s for LH and another company in the last 12 months.
- ADPTAdaptive Biotechnologies Peter M. Neupert Director here · Director at ADPT · latest filing Aug 19, 2026
- BBYBest Buy Richelle P. Parham Director here · Director at BBY · latest filing Nov 3, 2026
- DVADaVita Adam H. Schechter CEO, President here · Director at DVA · latest filing Nov 17, 2026
- FDXFFedEx Freight Jeffrey A. Davis Director here · Director at FDXF · latest filing Jul 1, 2026
- GPNGlobal Payments Kirsten Marie Kliphouse Director here · Director at GPN · latest filing May 4, 2026
- JNJJohnson & Johnson Kathryn E. Wengel Director here · Evp, Chief To And Risk Officer at JNJ · latest filing Jun 12, 2026
- SHWSherwin-Williams Kerrii B. Anderson Director here · Director at SHW · latest filing Oct 6, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
LH stock: common questions
Are Labcorp insiders buying LH stock?
No. No Labcorp insider reported an open-market purchase of LH in the past 12 months.
Are Labcorp insiders selling LH stock?
10 insiders reported sales worth $11.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is LH's P/E ratio?
LH trades at about 25.5 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is LH's 52-week range?
Over the past year LH has traded between $248.55 and $372.46. It last closed at $369.02 on Nov 19, 2026.